FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice

Zhang, Zheng; Lin, Tao; Meng, Yichen; Hu, Miao; Shu, Lun; Jiang, Heng; Gao, Rui; Ma, Jun; Wang, Ce; Zhou, Xuhui

doi:10.1016/j.metabol.2021.154767

Cited by 64 publications

(50 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that a leaky gut diet, together with anti-inflammatory and anti-oxidative substances, is able to significantly improve CFS conditions [ 149 ]. Moreover, the use of probiotics and/or prebiotics should also be considered, and preliminary studies in mice and rats show promising results [ 150 , 151 , 152 , 153 ]. Finally, positive outcomes were reported using fecal microbiota transplantation (FMT) in CFS patients [ 154 ], but further evidence is needed.…”

Section: Resultsmentioning

confidence: 99%

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Deumer

Varesi

Floris

et al. 2021

JCM

View full text Add to dashboard Cite

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic systemic disease that manifests via various symptoms such as chronic fatigue, post-exertional malaise, and cognitive impairment described as “brain fog”. These symptoms often prevent patients from keeping up their pre-disease onset lifestyle, as extended periods of physical or mental activity become almost impossible. However, the disease presents heterogeneously with varying severity across patients. Therefore, consensus criteria have been designed to provide a diagnosis based on symptoms. To date, no biomarker-based tests or diagnoses are available, since the molecular changes observed also largely differ from patient to patient. In this review, we discuss the infectious, genetic, and hormonal components that may be involved in CFS pathogenesis, we scrutinize the role of gut microbiota in disease progression, we highlight the potential of non-coding RNA (ncRNA) for the development of diagnostic tools and briefly mention the possibility of SARS-CoV-2 infection causing CFS.

show abstract

Section: Resultsmentioning

confidence: 99%

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Deumer

Varesi

Floris

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…GM is an essential mediator for the process of high-fat-induced bone loss and its abnormal change can alter the bone niche microenvironment ( Luo et al., 2015 ). Some previous studies have explored the effects of GM as a whole on bone metabolism related to HFD ( McCabe et al., 2019 ; Zhang et al., 2021 ). However, detailed characteristic analysis of GM and the metabolome has not been conducted, which may contribute to the identification of novel biomarkers and therapeutic targets.…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiota and Serum Metabolic Signatures of High-Fat-Induced Bone Loss in Mice

Tang

Jiao

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

BackgroundAccumulating evidence indicates that high-fat diet (HFD) is a controllable risk factor for osteoporosis, but the underlying mechanism remains to be elucidated. As a primary biological barrier for nutrient entry into the human body, the composition and function of gut microbiota (GM) can be altered rapidly by HFD, which may trigger abnormal bone metabolism. In the current study, we analyzed the signatures of GM and serum metabolomics in HFD-induced bone loss and explored the potential correlations of GM and serum metabolites on HFD-related bone loss.MethodsWe conducted a mouse model with HFD-induced bone loss through a 12-week diet intervention. Micro-CT, Osmium-μCT, and histological analyses were used to observe bone microstructure and bone marrow adipose tissue. Quantitative Real-Time PCR was applied to analyze gene expression related to osteogenesis, adipogenesis, and osteoclastogenesis. Enzyme-linked immunosorbent assay was used to measure the biochemical markers of bone turnover. 16s rDNA sequencing was employed to analyze the abundance of GM, and UHPLC-MS/MS was used to identify serum metabolites. Correlation analysis was performed to explore the relationships among bone phenotypes, GM, and the metabolome.ResultsHFD induced bone loss accompanied by bone marrow adipose tissue expansion and bone formation inhibition. In the HFD group, the relative abundance of Firmicutes was increased significantly, while Bacteroidetes, Actinobacteria, Epsilonbacteraeota, and Patescibacteria were decreased compared with the ND group. Association analysis showed that thirty-two bacterial genera were significantly related to bone volume per tissue volume (BV/TV). One hundred and forty-five serum metabolites were identified as differential metabolites associated with HFD intervention, which were significantly enriched in five pathways, such as purine metabolism, regulation of lipolysis in adipocyte and cGMP-PKG signaling pathway. Sixty-four diffiential metabolites were matched to the MS2 spectra; and ten of them were positively correlated with BV/TV and five were negatively correlated with BV/TV.ConclusionsThese findings indicated that the alternations of GM and serum metabolites were related to HFD-induced bone loss, which might provide new insights into explain the occurrence and development of HFD-related osteoporosis. The regulatory effects of GM and metabolites associated with HFD on bone homeostasis required further exploration.

show abstract

“…Given their ability to selectively promote the expansion of only some intestinal microorganisms and revising gut microbiota makeup and function [ 133 ], they are proposed as promising adjuvant therapy in many diseases (e.g., IBS, Crohn′s disease, bowel motility, autism, obesity and colorectal cancer) [ 133 ]. Multiple oligosaccharides have proven effective in reversing microbiota dysbiosis through Lactobacilli growth promotion, Proteobacteria reduction, and Firmicutes/Bacteroidetes ratio decrease in diet-induced obese rats and mice [ 135 , 136 , 137 ]. In addition, significant amelioration of gut permeability and systemic inflammation have also been reported.…”

Section: Main Findingsmentioning

confidence: 99%

“…In addition, significant amelioration of gut permeability and systemic inflammation have also been reported. Rats and mice fed with prebiotics, such as bovine milk oligosaccharides, oligofructose-enriched inulin, spirulina platensis, and FOS/GOS, showed lower plasma LPS, decrease in serum pro-inflammatory cytokine levels, reduced gut inflammation and improved tight-junction integrity [ 135 , 136 , 137 , 138 , 139 ]. Altogether, these studies suggest that prebiotics may be helpful for ME/CFS cases presenting dysbiosis, leaky gut and systemic basal inflammation, but clinical trials are needed before drawing further conclusions.…”

Section: Main Findingsmentioning

confidence: 99%

The Emerging Role of Gut Microbiota in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Current Evidence and Potential Therapeutic Applications

Varesi

Deumer

Ananth

et al. 2021

JCM

View full text Add to dashboard Cite

The well-known symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are chronic pain, cognitive dysfunction, post-exertional malaise and severe fatigue. Another class of symptoms commonly reported in the context of ME/CFS are gastrointestinal (GI) problems. These may occur due to comorbidities such as Crohn’s disease or irritable bowel syndrome (IBS), or as a symptom of ME/CFS itself due to an interruption of the complex interplay between the gut microbiota (GM) and the host GI tract. An altered composition and overall decrease in diversity of GM has been observed in ME/CFS cases compared to controls. In this review, we reflect on genetics, infections, and other influences that may factor into the alterations seen in the GM of ME/CFS individuals, we discuss consequences arising from these changes, and we contemplate the therapeutic potential of treating the gut to alleviate ME/CFS symptoms holistically.

show abstract

FOS/GOS attenuates high-fat diet induced bone loss via reversing microbiota dysbiosis, high intestinal permeability and systemic inflammation in mice

Cited by 64 publications

References 53 publications

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview

Gut Microbiota and Serum Metabolic Signatures of High-Fat-Induced Bone Loss in Mice

The Emerging Role of Gut Microbiota in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Current Evidence and Potential Therapeutic Applications

Contact Info

Product

Resources

About